Literature DB >> 8074962

Cardiac PET: microcirculation and substrate transport in normal and diseased human myocardium.

H R Schelbert1.   

Abstract

The development and validation of quantitative assay techniques for the noninvasive study of human myocardium has opened up new avenues for the study of the normal and diseased human heart's physiology. Measurements of regional myocardial blood flow, which delineates nutrient rather than coronary blood flow, has enabled the exploration of the coronary microcirculatory physiology under normal and abnormal conditions. It permits the study of pharmacologic effects and of cardiovascular disease on the coronary resistance and capillary perfusion. If combined with metabolic assay techniques, the transcapillary exchange of substrates in oxygen can be quantified and changes imposed by physiologic interventions and substrate metabolism being measured. These study approaches further serve to characterize changes in response to reductions in coronary blood flow as well as altered states of potentially reversible contractile function. It is anticipated that further studies with PET will clarify at the microcirculatory level the changes associated with ischemia, post-ischemic stunning and myocardial hibernation. Further, it offers the possibility to measure potentially beneficial effects of therapeutic interventions or, alternatively, to provide a rationale for novel therapeutic approaches.

Entities:  

Mesh:

Year:  1994        PMID: 8074962     DOI: 10.1007/bf03165013

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  27 in total

1.  Quantification of regional myocardial blood flow using 13N-ammonia and reoriented dynamic positron emission tomographic imaging.

Authors:  W G Kuhle; G Porenta; S C Huang; D Buxton; S S Gambhir; H Hansen; M E Phelps; H R Schelbert
Journal:  Circulation       Date:  1992-09       Impact factor: 29.690

Review 2.  Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity.

Authors:  N A Flavahan
Journal:  Circulation       Date:  1992-05       Impact factor: 29.690

3.  Issues in the quantitation of reoriented cardiac PET images.

Authors:  W G Kuhle; G Porenta; S C Huang; M E Phelps; H R Schelbert
Journal:  J Nucl Med       Date:  1992-06       Impact factor: 10.057

4.  Interrelations between coronary artery pressure, myocardial metabolism and coronary blood flow.

Authors:  E O Feigl; G W Neat; A H Huang
Journal:  J Mol Cell Cardiol       Date:  1990-04       Impact factor: 5.000

5.  Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography.

Authors:  P Camici; G Chiriatti; R Lorenzoni; R C Bellina; R Gistri; G Italiani; O Parodi; P A Salvadori; N Nista; L Papi
Journal:  J Am Coll Cardiol       Date:  1991-03-15       Impact factor: 24.094

6.  Effects of age and exercise on the extent of the myocardial capillary bed.

Authors:  R J Tomanek
Journal:  Anat Rec       Date:  1970-05

7.  N-13 ammonia as an indicator of myocardial blood flow.

Authors:  H R Schelbert; M E Phelps; S C Huang; N S MacDonald; H Hansen; C Selin; D E Kuhl
Journal:  Circulation       Date:  1981-06       Impact factor: 29.690

8.  Comparison of maximal myocardial blood flow during adenosine infusion with that of intravenous dipyridamole in normal men.

Authors:  S Y Chan; R C Brunken; J Czernin; G Porenta; W Kuhle; J Krivokapich; M E Phelps; H R Schelbert
Journal:  J Am Coll Cardiol       Date:  1992-10       Impact factor: 24.094

9.  Flow-dependent coronary artery dilatation in humans.

Authors:  H Drexler; A M Zeiher; H Wollschläger; T Meinertz; H Just; T Bonzel
Journal:  Circulation       Date:  1989-09       Impact factor: 29.690

View more
  1 in total

1.  Clinical cardiac PET: quo vadis?

Authors:  H R Schelbert; J Maddahi
Journal:  J Nucl Cardiol       Date:  1994 Nov-Dec       Impact factor: 5.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.